One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis.
Hook EW 3rd, Dionne JA, Workowski K, McNeil CJ, Taylor SN, Batteiger TA, Dombrowski JC, Mayer KH, Seña AC, Hamill MM, Wiesenfeld HC, Zhu C, Perlowski C, Mejia-Galvis JE, Newman LM
- DOI
- 10.1056/NEJMoa2401802
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-21
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/853e17a1-fd8a-4dcd-a33e-9b447c7bb26c is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×4−2★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- ReportingData & code availability partially met−0.25★
- No reported statistical tests were found to recompute.
- No data or code availability links were detected to verify.
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy endpoint is a ≥4-fold decline in RPR titer at 6 months, which is a serological surrogate for clinical cure. The paper does not provide evidence of target engagement (e.g., PK/PD data) at the tested dose, nor does it cite validated evidence linking RPR seroreversion to long-term clinical outcomes such as prevention of neurosyphilis or cardiovascular complications. The authors themselves acknowledge that serologic response is an imperfect measure.
“A further limitation of the study is our continued reliance upon serological response to therapy as an indicator of therapeutic effect (, ). Serologic response is an imperfect measure as it may take months to occur and even after as long as six months…”
- 02Treatment effect not shown to be clinically meaningful
The primary outcome is a non-inferiority comparison of serological response rates (76% vs 70%), with a pre-specified non-inferiority margin of 10%. The effect size is presented as a difference in proportions, but there is no anchor to a minimal clinically important difference or to clinical meaningfulness. The response rates themselves are not compared to a known benchmark for cure, and the paper does not establish that a 76% serological response rate is clinically adequate.
“the serological response rate was 76% (95% Wilson CI 68–82%) in the single treatment group and 70% (95% Wilson CI 61–77%) in the three treatment group”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted multicenter randomized non-inferiority trial with a clear premise, rigorous design, and transparent reporting. The main weaknesses are the lack of a data availability statement, missing trial registration number, and several minor reporting gaps (randomization method, statistical software, CONSORT statement). The copyedit pass identified numerous inconsistencies in Table 1 that need correction.
Both reviewers classified the study as interventional, and I adopt that classification. The evaluation covered the full text, including methods, results, and discussion. Non-applicable sub-criteria (e.g., animal-related, cell line authentication) were excluded. The statistics verification component checked 0 tests, so no independent statistical verification was possible; the integrity check flagged internal contradictions in Table 1 that are addressed in the action items.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
- lowinternal contradictionTable 1 RPR titer distribution totals do not sum to the group totals (e.g., 1:1 row shows total 2 but individual groups sum to 3).
“1:1 | 2 (2%) | 1 (1%) | 2 (1%)”
Table 1Find in source - lowinternal contradictionThe abstract reports 76% vs 71% for HIV subgroups, but Table 3A shows 76% vs 71% for PWH and 76% vs 70% for non-PWH.
“76% in the single dose group vs. 71% in the 3-dose group”
Table 3AFind in source - lowinternal contradictionThe total column for several RPR titer rows appears inconsistent with the sum of the two groups.
“1:2 | 6 (5%) | 0 (0%) | 2 (1%)”
Table 1Find in source - lowinternal contradictionThe abstract reports 153 (64%) living with HIV, but Table 1 shows 153 (61%) and text says 61%.
“153 (64%) were living with HIV”
Table 1Find in source
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions only partially backed by the presented evidenceAssessed
5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewers 1, 2A single treatment using 2.4 MU should be the preferred treatment for early syphilis.The trial supports non-inferiority, but the claim of 'preferred' is a clinical recommendation beyond the direct evidence.Evidence: Non-inferiority result and discussion of benefits.
“With no observable benefit to multiple treatments, a single treatment using 2.4 MU should be, in our opinion, the preferred treatment for early syphilis.”
DiscussionFind in source - supportedReviewers 1, 2Single-dose BPG is non-inferior to three-dose BPG for early syphilis treatment.The primary outcome analysis shows the upper CI of the difference is below the non-inferiority margin.Evidence: Farrington-Manning test result: difference −0.06 [90% CI (−0.15, 0.03)], upper limit 0.03 < 0.10.
“The upper confidence limit, 0.03, is less than the non-inferiority margin of 0.10, indicating that the single BPG treatment was non-inferior to three successive weekly treatments with 2.4 MU of BPG.”
ResultsFind in source - supportedReviewer 1No clinical relapses or treatment failures occurred.The paper states no clinical relapses or treatment failures occurred, and the evaluable analysis had no treatment failures.Evidence: Abstract states 'No clinical relapses or treatment failures occurred.'
“No clinical relapses or treatment failures occurred.”
AbstractFind in source - supportedReviewers 1, 2Treatment with more than a single dose of BPG offers no benefit at 6 months post-treatment, irrespective of HIV infection status.The non-inferiority result and subgroup analyses support this claim.Evidence: Non-inferiority shown overall and in HIV subgroups.
“Treatment with more than a single dose of 2.4 MU of BPG offers no benefit at 6 months post-treatment, irrespective of HIV infection status.”
ConclusionFind in source - supportedReviewer 2There is no significant difference in RPR response at 6 months between single and three-dose groups among persons with and without HIV.The reported response rates and confidence intervals overlap, and the paper states no significant difference.Evidence: Among persons with and without HIV there was no significant difference in RPR response at 6 months: 76% in the single dose group vs. 71% in the 3-dose group (90% CI −0.05 0–0.17,0.07).
Among persons with and without HIV there was no significant difference in RPR response at 6 months: 76% in the single dose group vs. 71% in the 3-dose group (90% CI −0.05 0–0.17,0.07).
Abstractreviewer’s wording
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy endpoint is a ≥4-fold decline in RPR titer at 6 months, which is a serological surrogate for clinical cure. The paper does not provide evidence of target engagement (e.g., PK/PD data) at the tested dose, nor does it cite validated evidence linking RPR seroreversion to long-term clinical outcomes such as prevention of neurosyphilis or cardiovascular complications. The authors themselves acknowledge that serologic response is an imperfect measure.
“A further limitation of the study is our continued reliance upon serological response to therapy as an indicator of therapeutic effect (, ). Serologic response is an imperfect measure as it may take months to occur and even after as long as six months following the initiation of therapy, about 20% of persons treated for early syphilis have no significant change in RPR titers”
- INADEQUATEEffect sizeThe primary outcome is a non-inferiority comparison of serological response rates (76% vs 70%), with a pre-specified non-inferiority margin of 10%. The effect size is presented as a difference in proportions, but there is no anchor to a minimal clinically important difference or to clinical meaningfulness. The response rates themselves are not compared to a known benchmark for cure, and the paper does not establish that a 76% serological response rate is clinically adequate.
“the serological response rate was 76% (95% Wilson CI 68–82%) in the single treatment group and 70% (95% Wilson CI 61–77%) in the three treatment group”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The introduction cites historical context and prior studies on syphilis treatment, acknowledges ongoing controversy regarding optimal BPG duration, and clearly links the premise to the trial's objective. Limitations of prior research are implicitly addressed by the trial design, though not explicitly detailed.
“To address the continuing controversy regarding the optimal duration of BPG for early syphilis treatment, we conducted a multicenter randomized non-inferiority clinical trial (RCT) comparing single dose therapy with 2.4 million units (MU) of BPG to therapy with three doses of 2.4MU BPG administered at successive weekly intervals.”
“While a single dose of benzathine penicillin G (BPG) has been the accepted standard for therapy of early (primary, secondary, early latent) syphilis for decades, concerns about the adequacy of single dose BPG for treatment of early syphilis for persons with HIV (PWH) are longstanding.”
Randomization method is not explicitly described but is implied by 'randomized' and 1:1 allocation. Blinding is open-label, which is acceptable for a drug administration trial. Power analysis is reported with a pre-specified non-inferiority margin and sample size calculation. Inclusion/exclusion criteria are detailed. Outlier handling is addressed through ITT and per-protocol analyses. Controls are not applicable as this is a comparative trial. Independent replication is not applicable for a single pivotal trial.
“Participants were randomized to receive either a single BPG treatment or a series of three successive BPG treatments administered at weekly intervals.”
“This open label RCT was conducted at ten U.S. sites.”
“The pre-specified non-inferiority margin was 10%. The null hypothesis specified a response rate of 0.688 for the one-dose regimen and 0.788 for the three-dose regimen with a one-sided alpha of 0.05. Using these parameters a sample size of 420 participants (210 per treatment group) was sought.”
“This open label RCT was conducted at ten U.S. sites.”
“The pre-specified non-inferiority margin was 10%. The null hypothesis specified a response rate of 0.688 for the one-dose regimen and 0.788 for the three-dose regimen with a one-sided alpha of 0.05. Using these parameters a sample size of 420 participants (210 per treatment group) was sought.”
Sex, age, race, ethnicity, and HIV status are reported in Table 1. Since both sexes are enrolled, sex_justified is not applicable. Age and health status (HIV, CD4 counts) are reported. Demographics are comprehensive.
The paper states that the master protocol was approved by the UAB IRB and subsequently by each site's IRB. Written informed consent was obtained from all participants. Regulatory compliance is implied by IRB approval and adherence to standard practices.
“The master protocol was approved by the UAB Institutional Review Board (IRB) for Human Subjects and subsequently by IRBs at each study site.”
“Written informed consent was obtained from all participants.”
“Written informed consent was obtained from all participants. The master protocol was approved by the UAB Institutional Review Board (IRB) for Human Subjects and subsequently by IRBs at each study site.”
The drug benzathine penicillin G is named with dose and regimen. The RPR and TPPA tests are identified with manufacturers. Statistical software is not explicitly named, but the Farrington-Manning test is mentioned. Since this is a drug trial, bench criteria are not applicable.
“BPG 2.4 million units (MU)”
The Farrington-Manning test is named. Effect sizes are reported with 95% CIs. Exact p-values are not reported, but the trial uses estimation with CIs, which is acceptable. Statistical software is not identified. Data presentation includes CONSORT flow diagram and per-group n. Mathematical plausibility is not applicable due to large N and continuous outcomes.
“Differences in response rate using the Farrington-Manning test were compared without adjustment for HIV status.”
“The Farrington-Manning test result showed the difference in the proportion of participants with serological response between the two treatment groups as −0.06 [90% CI (−0.15, 0.03)].”
“Differences in response rate using the Farrington-Manning test were compared without adjustment for HIV status.”
“The Farrington-Manning test result showed the difference in the proportion of participants with serological response between the two treatment groups as −0.06 [90% CI (−0.15, 0.03)].”
The paper mentions the protocol and SAP at nejm.org, but no data availability statement is present. No repository deposit or accession numbers are provided. Since this is a clinical trial with patient data, repository deposit and accession numbers are not applicable, but a data availability statement is required and missing.
Methods are detailed. Trial registration is not mentioned, but this may be a pre-print. Reporting guideline (CONSORT) is referenced via the flow diagram. All outcomes are reported. Limitations are discussed. Conclusions are proportional. Funding and COI are provided.
“Our study had several limitations. The number of women in the trial was low.”
“This work was funded by the National Institute of Allergy and Infectious Diseases (Sexually Transmitted Infections Clinical Trials Group) Contract HHSN272201300012I.”
“Our study had several limitations. The number of women in the trial was low.”
“This work was funded by the National Institute of Allergy and Infectious Diseases (Sexually Transmitted Infections Clinical Trials Group) Contract HHSN272201300012I.”
No trial/study registration detected. Reporting guideline cited: CONSORT.
Broken references and links
None found · partly checkedReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.
Checked 14 references by DOI: 3 verified — 11 no DOI (shown, not verified).
- NO DOISTI Surveillance Report. 2023No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe introduction of penicillin for the treatment of syphilisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITreatment for Early Syphilis and Reactivity of Serological TestsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIClinical Reminders during Bicillin L-A ® ShortageNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA manual of tests for syphilisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIRapid plasma reagin titer variation in the 2 weeks after syphilis therapyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe treatment of early syphilis with penicillin. A preliminary report of 1,418 casesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAssessment of country implementation of the WHO global health sector strategy on sexually transmitted infections (2016–2021)No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAntibiotic AllergyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEvaluation and management of penicillin allergy: A reviewNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPredictors of serological cure and the serofast state after treatment in HIV-negative persons with early syphilisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
Copyediting
22 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 22 minor suggestions below.
22 copyedit issues flagged: mostly consistency, typo.
- MINORtypoAbstract, Results“90% CI −0.05 0–0.17,0.07”→ Correct to '90% CI −0.05 to 0.17'Malformed CI notation.
- MINORconsistencyTable 1, RPR Titer rows“1:1 | 2 (2%) | 1 (1%) | 2 (1%)”→ Ensure totals match sum of columnsTotal for 1:1 appears incorrect (2+1=3, not 2).
- MINORconsistencyTable 1, RPR Titer rows“1:32 | 31 (25%) | 20 (16%) | 41 ((16)”→ Correct formatting and ensure totalTotal 41 is correct (31+20=51? Actually 31+20=51, so 41 is wrong).
- MINORconsistencyTable 1, RPR Titer rows“>1:512 | 2 (2%) | 3 (2%) | (blank)”→ Provide totalTotal missing.
- MINORtypoTable 1, Study Site Location“Baton Rouge, Louisiana | 16 (13%) | 16 (13%) | 32 (13%)”→ Correct state abbreviationShould be 'LA' not 'Louisiana' for consistency.
- MINORtypoTable 1, Study Site Location“Baltimore, MD | 2 (2%) | 2 (2%) | 4 (2)”→ Add percent signMissing % in total.
- MINORtypoTable 1, Study Site Location“Pittsburgh, PA | 2 (2%) | 1 (1%) | 3 (1%)”→ Correct percent3/249 is 1.2%, so 1% is fine.
- MINORtypoAbstract, Results“90% CI −0.05 0–0.17,0.07”→ Correct the CI notation to a consistent format, e.g., 90% CI (−0.05, 0.17).The CI is written with inconsistent separators.
- MINORconsistencyTable 1, RPR Titer rows“1:1 | 2 (2%) | 1 (1%) | 2 (1%)”→ Ensure the total column sums correctly; the total for 1:1 appears to be 2, but the individual columns sum to 3.The total column for RPR titer 1:1 shows 2 (1%) but the sum of the two groups is 3.
- MINORconsistencyTable 1, RPR Titer rows“1:2 | 6 (5%) | 0 (0%) | 2 (1%)”→ Check the total for 1:2; it should be 6, not 2.The total column for 1:2 shows 2 (1%) but the one-dose group has 6.
- MINORconsistencyTable 1, RPR Titer rows“1:4 | 9 (7%) | 5 (4%) | 11 (4%)”→ Check the total for 1:4; it should be 14, not 11.The total column for 1:4 shows 11 (4%) but the sum of the two groups is 14.
- MINORconsistencyTable 1, RPR Titer rows“1:8 | 4 (3%) | 7 (6%) | 16 (6%)”→ Check the total for 1:8; it should be 11, not 16.The total column for 1:8 shows 16 (6%) but the sum of the two groups is 11.
- MINORconsistencyTable 1, RPR Titer rows“1:16 | 21 (17%) | 11 (9%) | 16 (6%)”→ Check the total for 1:16; it should be 32, not 16.The total column for 1:16 shows 16 (6%) but the sum of the two groups is 32.
- MINORconsistencyTable 1, RPR Titer rows“1:32 | 31 (25%) | 20 (16%) | 41 ((16)”→ Correct the total percentage to (16%) and ensure the total count is 51.The total column for 1:32 shows 41 ((16) but the sum of the two groups is 51.
- MINORconsistencyTable 1, RPR Titer rows“1:64 | 28 (22%) | 28 (23%) | 59 (24%)”→ Check the total for 1:64; it should be 56, not 59.The total column for 1:64 shows 59 (24%) but the sum of the two groups is 56.
- MINORconsistencyTable 1, RPR Titer rows“1:128 | 12 (10%) | 25 (20%) | 53 (21%)”→ Check the total for 1:128; it should be 37, not 53.The total column for 1:128 shows 53 (21%) but the sum of the two groups is 37.
- MINORconsistencyTable 1, RPR Titer rows“1:256 | 1 (1%) | 16 (13%) | 28 (11%)”→ Check the total for 1:256; it should be 17, not 28.The total column for 1:256 shows 28 (11%) but the sum of the two groups is 17.
- MINORconsistencyTable 1, RPR Titer rows“1:512 | 4 (3%) | 4 (3%) | 5 (2%)”→ Check the total for 1:512; it should be 8, not 5.The total column for 1:512 shows 5 (2%) but the sum of the two groups is 8.
- MINORconsistencyTable 1, RPR Titer rows“>1:512 | 2 (2%) | 3 (2%) | |”→ Provide the total count and percentage for the >1:512 row.The total column is missing for the >1:512 row.
- MINORtypoTable 1, Study Site Location“Baltimore, MD | 2 (2%) | 2 (2%) | 4 (2)”→ Add a percent sign to the total: 4 (2%).Missing percent sign in the total column.
- MINORtypoTable 1, Study Site Location“Pittsburgh, PA | 2 (2%) | 1 (1%) | 3 (1%)”→ Check the total percentage; it should be 1% but the sum is 3.The total percentage is 1% but the count is 3, which is 1.2% of 249.
- MINORtypoTable 1, RPR Titer“Geometric Mean RPR Titer (95% CI) | 57.1 (44.2, 73.5) | 60.0 (47.5. 75.9) | 58.5 (49.3, 69.5)”→ Correct the decimal separator in the three-dose CI: 60.0 (47.5, 75.9).The three-dose CI uses a period instead of a comma.
The published work is methodologically robust, but an informed reader should weigh the missing data availability statement, the lack of trial registration, and the internal inconsistencies in Table 1. These issues do not invalidate the conclusions but warrant a correction or clarification from the authors.
- 1.HIGHdata codeAdd a data availability statement in the Methods or a dedicated section, specifying how de-identified data can be accessed (e.g., via a data access committee or repository).The paper currently lacks any data availability statement, which is a requirement for most journals and a key transparency element.
- 2.HIGHcopyeditCorrect the internal inconsistencies in Table 1 RPR titer totals (e.g., 1:1 row shows total 2 but groups sum to 3; 1:32 total shows 41 but groups sum to 51; several other rows have mismatched totals).These numerical inconsistencies undermine the credibility of the data presentation and could be interpreted as data errors.
- 3.HIGHreportingInclude the clinical trial registration number (e.g., ClinicalTrials.gov) in the Methods or Abstract.Trial registration is a standard requirement for clinical trials and is currently missing.
- 4.HIGHreportingExplicitly state adherence to CONSORT guidelines for reporting randomized trials.While a CONSORT flow diagram is referenced, the paper does not explicitly state CONSORT adherence, which is expected for RCTs.
- 5.HIGHstatisticsSpecify the statistical software used for analyses (e.g., SAS, R) with version in the Statistical Analyses section.Identifying the software is part of methodological transparency and reproducibility.
- 6.HIGHrigorDescribe the randomization method (e.g., computer-generated random sequence, block randomization) in the Methods.The randomization method is not described, which is a key methodological detail for assessing bias.
- 7.MEDIUMethicsAdd a statement that the study was conducted in accordance with the Declaration of Helsinki or other ethical standards.While IRB approval is stated, explicit mention of ethical standards is a common requirement.
- 8.MEDIUMcopyeditCorrect the malformed CI notation in the Abstract: '90% CI −0.05 0–0.17,0.07' should be '90% CI (−0.05, 0.17)'.The current notation is confusing and could be misread.
- 9.MEDIUMcopyeditFix the decimal separator in Table 1 Geometric Mean RPR Titer: '60.0 (47.5. 75.9)' should be '60.0 (47.5, 75.9)'.The period instead of comma is a typographical error that could cause confusion.
- 10.MEDIUMcopyeditEnsure all percentages in Table 1 have percent signs and are consistent (e.g., '4 (2)' should be '4 (2%)').Missing percent signs and inconsistent formatting reduce clarity.
- 11.LOWcopyeditStandardize state abbreviations in Table 1 (e.g., 'Louisiana' to 'LA') for consistency.Consistency in formatting improves readability.
- 12.LOWrigorAdd a brief statement in the Introduction on how limitations of prior research were addressed.This would strengthen the scientific premise by explicitly acknowledging gaps in prior work.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.